NASDAQ:NEUP Neuphoria Therapeutics Inc. - Common Stock (NEUP) Stock Price, News & Analysis $5.05 +0.05 (+1.00%) As of 05/2/2025 03:24 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock About Neuphoria Therapeutics Inc. - Common Stock Stock (NASDAQ:NEUP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NEUP alerts:Sign Up Key Stats Today's Range$4.93▼$5.2550-Day Range$4.64▼$5.8052-Week Range$2.12▼$15.24Volume9,423 shsAverage Volume416,957 shsMarket Capitalization$8.87 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Read More… Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics Inc. - Common Stock and its competitors with MarketBeat's FREE daily newsletter. Email Address NEUP Stock News HeadlinesNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 4, 2025 | Golden Portfolio (Ad)Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics Inc. - Common Stock's stock was trading at $3.20 at the beginning of the year. Since then, NEUP stock has increased by 57.8% and is now trading at $5.05. View the best growth stocks for 2025 here. How were Neuphoria Therapeutics Inc. - Common Stock's earnings last quarter? Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) issued its earnings results on Friday, February, 14th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.01) by $0.78. The firm had revenue of $660 billion for the quarter. Who are Neuphoria Therapeutics Inc. - Common Stock's major shareholders? Neuphoria Therapeutics Inc. - Common Stock's top institutional investors include Cyndeo Wealth Partners LLC (0.57%). How do I buy shares of Neuphoria Therapeutics Inc. - Common Stock? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/14/2025Today5/03/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.bionomics.com.au Phone61-8-8150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+315.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.06 Quick Ratio3.30 Sales & Book Value Annual Sales$662,715.00 Price / Sales13.39 Cash FlowN/A Price / Cash FlowN/A Book Value$7.82 per share Price / Book0.65Miscellaneous Outstanding Shares1,757,000Free Float1,745,000Market Cap$8.87 million OptionableN/A Beta0.25 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NEUP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. - Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics Inc. - Common Stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.